EGF-R Protein Expression and Gene Amplification Do Not Correlate in Pancreas Cancer
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
In a series of 13 pancreas cancer specimens, EGF-R was evaluated by means of both immunohistochemistry (IHC) for protein expression and FISH for genetic amplification. The results were discording in 7 cases (IHC positive, FISH negative), while in the remaining 6 cases both IHC and FISH were negative. The possible clinical implications of these results are discussed.
References
1.
Shirk A, Kuver R
. Epidermal growth factor mediates detachment from and invasion through collagen I and Matrigel in Capan-1 pancreatic cancer cells. BMC Gastroenterol. 2005; 5:12.
PMC: 1079814.
DOI: 10.1186/1471-230X-5-12.
View
2.
Dragovich T, Huberman M, Von Hoff D, Rowinsky E, Nadler P, Wood D
. Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial. Cancer Chemother Pharmacol. 2006; 60(2):295-303.
DOI: 10.1007/s00280-006-0389-0.
View
3.
Moore M, Goldstein D, Hamm J, Figer A, Hecht J, Gallinger S
. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25(15):1960-6.
DOI: 10.1200/JCO.2006.07.9525.
View
4.
Pham N, Schwock J, Iakovlev V, Pond G, Hedley D, Tsao M
. Immunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis. BMC Cancer. 2008; 8:43.
PMC: 2270852.
DOI: 10.1186/1471-2407-8-43.
View